Eli Lilly's Tirzepatide Meets Main Endpoints in Phase 3 Obes

By Colin Kellaher


Eli Lilly & Co. on Thursday said a Phase 3 study of its diabetes drug candidate tirzepatide met its key endpoints in obese or overweight adults who don't have diabetes.... | April 28, 2022

Related Keywords

Colin Kellaher , Eli Lilly , Drug Administration , Eli Lilly Co , Dow Jones , Eli Lilly And Company Stock Exchange , News , Information , Press Release , Y , Colin , Kellaher , Mali , Illy , N , Hursday , Aid , Hase , , Study , F , Its , Diabetes , Drug , Candidate , Tirzepatide , Pet , Key , Endpoints , Bese , Dr , Verweight , Adults , Who , Ave Lly Us5324571083 ,